Journal article icon

Journal article

Tissue Damage in Rheumatoid Arthritis Is Genetically Linked to Low Peptidylglycine Alpha‐Amidating Monooxygenase Activity in Synovial Fibroblasts

Abstract:
Objective: Both susceptibility to, and severity of, rheumatoid arthritis (RA) is associated with the rs26232 C allele. Our primary aim was to identify the biologic mechanism underlying this association. Methods: Expression of surrounding genes was compared among rs26232 genotypes. Publicly available databases were used to correlate expression with RA inflammation and single‐cell synovial distribution. Inhibition of gene expression and activity was achieved using small interfering RNA and a pharmacology agent and effects on RA synovial fibroblasts (RASFs) characteristics in vitro were assayed. The amidated secretome of synovial fibroblasts were characterized by mass spectrometry and enzyme‐linked immunosorbent assay. Effects of amidated peptides on macrophage polarity were determined using an RASF–macrophage coculture module. Results: rs26232 C is associated with low expression of peptidylglycine alpha‐amidating monooxygenase (PAM) in multiple tissues including RASFs. Synovial PAM is highly expressed in RASFs but not immune cells, and levels are inversely correlated with synovial and systemic levels of inflammation. Inhibition of PAM in RASFs increased tissue‐damaging activities such as invasiveness in vitro. The most abundant amidated peptides secreted by RASFs were adrenomedullin (ADM) and pro‐ADM N‐terminal peptide (PAMP). Incubation of RASFs with either peptide inhibited interleukin‐6 (IL‐6) and IL‐8, increased transforming growth factor β production, and reduced invasiveness in vitro. Inhibition of amidation in an RASF–macrophage coculture model skewed the macrophages to proinflammatory MerTK− phenotypes. Conclusion: Genetically determined low PAM reduces the anti‐inflammatory and tissue‐damaging activities of ADM and PAMP mediated by macrophages and RASFs, explaining the association of rs26232 C with RA severity.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1002/art.70123

Authors

More by this author
Role:
Author
ORCID:
0000-0002-1061-073X
More by this author
Role:
Author
ORCID:
0000-0003-2014-934X
More by this author
Role:
Author
ORCID:
0009-0001-5200-2724


More from this funder
Funder identifier:
https://ror.org/003hb2249
Grant:
ILP‐POR‐2022‐014


Publisher:
Wiley
Journal:
Arthritis & Rheumatology More from this journal
Article number:
art.70123
Publication date:
2026-04-14
Acceptance date:
2026-02-05
DOI:
EISSN:
2326-5205
ISSN:
2326-5191


Language:
English
Keywords:
Pubs id:
2392700
Local pid:
pubs:2392700
Source identifiers:
3948183
Deposit date:
2026-04-21
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP